Phibro Animal Health (NASDAQ:PAHC) was downgraded by research analysts at ValuEngine from a “buy” rating to a “hold” rating in a research note issued on Monday.
A number of other research firms have also recently weighed in on PAHC. BidaskClub cut shares of Phibro Animal Health from a “buy” rating to a “hold” rating in a research report on Thursday, August 16th. Morgan Stanley upped their price objective on shares of Phibro Animal Health from $36.00 to $46.00 and gave the company an “underweight” rating in a research report on Wednesday, August 29th. Finally, Zacks Investment Research raised shares of Phibro Animal Health from a “sell” rating to a “buy” rating and set a $53.00 price objective for the company in a research report on Thursday, August 30th. Four research analysts have rated the stock with a sell rating and two have assigned a hold rating to the stock. The stock presently has a consensus rating of “Sell” and a consensus target price of $43.50.
NASDAQ:PAHC opened at $36.56 on Monday. The company has a debt-to-equity ratio of 1.62, a current ratio of 3.26 and a quick ratio of 1.82. The stock has a market capitalization of $1.50 billion, a price-to-earnings ratio of 21.01, a PEG ratio of 3.13 and a beta of 0.82. Phibro Animal Health has a 1-year low of $32.05 and a 1-year high of $54.62.
In other news, insider Dean J. Warras sold 10,000 shares of the company’s stock in a transaction dated Thursday, November 1st. The shares were sold at an average price of $42.84, for a total value of $428,400.00. Following the sale, the insider now owns 10,000 shares in the company, valued at approximately $428,400. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Jack Bendheim sold 30,000 shares of the company’s stock in a transaction dated Thursday, August 23rd. The shares were sold at an average price of $50.04, for a total transaction of $1,501,200.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 93,020 shares of company stock worth $4,481,471. Company insiders own 50.29% of the company’s stock.
Institutional investors have recently modified their holdings of the company. Quantbot Technologies LP acquired a new stake in shares of Phibro Animal Health in the 3rd quarter valued at about $115,000. Royal Bank of Canada raised its stake in Phibro Animal Health by 2,104.6% during the first quarter. Royal Bank of Canada now owns 3,814 shares of the company’s stock worth $151,000 after acquiring an additional 3,641 shares during the period. Meeder Asset Management Inc. raised its stake in Phibro Animal Health by 149.2% during the second quarter. Meeder Asset Management Inc. now owns 4,470 shares of the company’s stock worth $206,000 after acquiring an additional 2,676 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new stake in Phibro Animal Health during the third quarter worth about $206,000. Finally, Piedmont Investment Advisors LLC acquired a new stake in Phibro Animal Health during the second quarter worth about $213,000. Institutional investors and hedge funds own 48.25% of the company’s stock.
Phibro Animal Health Company Profile
Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition company primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture.
Recommended Story: What is Cost of Debt?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.